-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Category Archives: Idiopathic Pulmonary Fibrosis
December 01 2013 – Human stem cells converted to functional lung cells
NEW YORK, NY — For the first time, scientists have succeeded in transforming human stem cells into functional lung and airway cells. The advance, reported by Columbia University Medical Center (CUMC) researchers, has significant potential for modeling lung disease, screening … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
Surgeons at Global Health City have performed a minimally-invasive lung transplant on a 60-year-old patient, who has been suffering from idiopathic pulmonary fibrosis for the last 11 years. The lung transplant was done through a seven-inch-long incision, which is nearly … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical News, NAC, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
SAN FRANCISCO–(BUSINESS WIRE)–FibroGen, Inc. (FibroGen), announced today that interim results from an ongoing open-label Phase 2 clinical study to evaluate FG-3019 as a treatment for idiopathic pulmonary fibrosis (IPF) continue to suggest that the investigational drug has the potential to … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
Enzo Biochem Inc. (NYSE:ENZ) today announced publication of a study in a leading scientific journal Modern Pathology a Nature Publishing Group publication that shows a strong association of idiopathic pulmonary fibrosis (IPF) a pulmonary disease with 100% mortality within five … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, IPF, Lung Transplant, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
ST. LOUIS – A team of scientists that includes Saint Louis University researchers has identified a new way to intervene in the molecular and cellular cascade that causes fibrosis – a condition where the body’s natural process of forming scars … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, www.ipftoday.com
Leave a comment
November 4 2013 – Development Plan for PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
Worldwide, there are over 5,000,000 people living with Idiopathic Pulmonary Fibrosis (IPF)(IPF Coalition).IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
October 28 2013 – Ambrisentan (Letairis) stopped early in IPF trial (Annals Int Med)
Ambrisentan (Letairis) stopped early in IPF trial A large phase III randomized trial testing Ambrisentan (Letairis) for early idiopathic pulmonary fibrosis was stopped early after an interim analysis of the data showed possible harm. The results were reported in Annals of … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
October 21 2013 – Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study
Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study Original Text Prof Ferran Morell MD a b , Ana Villar MD a b, María-Ángeles Montero MD c d †, Xavier Muñoz MD a b, Prof … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, IPF, Lung Transplant, Medical, NAC, Nintedanib, Pirfenidone, Promedior, www.ipftoday.com
Leave a comment
October 18 2013 – UW researchers to test novel therapy for idiopathic pulmonary fibrosis
Dear Colleagues: I am very pleased to report that UW researchers have received a grant from the National Institutes of Health (NIH) to test a promising, novel surgical therapy for treating idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Pirfenidone, Promedior, www.ipftoday.com
Leave a comment
October 13 2013 – Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice
Despite the established role of alveolar type II epithelial cells for the maintenance of pulmonary function, little is known about the deregulation of lipid composition in the pathogenesis of pulmonary fibrosis. The elongation of long-chain fatty acids family member 6 … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Curcumin 95, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Interstitial Lung Disease, IPF, Lung Transplant, Medical, Medical News, NAC, Nintedanib, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
